Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series  by Wu, Jiang-nan et al.
International Journal of Infectious Diseases 51 (2016) 62–65Association between timely initiation of hepatitis B vaccine and
completion of the hepatitis B vaccine and national immunization
program vaccine series
Jiang-nan Wua,*, Da-jin Li a, Yong Zhou b
aDepartment of Clinical Epidemiology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, PR China
b Fujian Provincial Centers for Disease Control and Prevention, Fuzhou, PR China
A R T I C L E I N F O
Article history:
Received 17 June 2016
Received in revised form 22 August 2016
Accepted 23 August 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Hepatitis B vaccine
Birth dose
National immunization program vaccine
S U M M A R Y
Background: Little is known about the association between the initiation of hepatitis B vaccine (HB
vaccine) at birth and completion of the HB vaccine and the national immunization program vaccine
(NIPV) series in Fujian, China.
Methods: A provincial survey, including children in the community and newborns in hospital, was
conducted to evaluate coverage with a timely ﬁrst dose of HB vaccine and the completion of three doses
of HB vaccine and the NIPV series in 2013. A proportion of the samples was rechecked to investigate the
relationship between the administration of a timely ﬁrst dose of HB vaccine and completion of the HB
vaccine series and the NIPV series (three doses of HB vaccine, one dose of Bacillus Calmette–Gue´rin
vaccine, three doses of oral poliomyelitis vaccine, three doses of diphtheria–tetanus–pertussis vaccine,
one dose of measles-containing vaccine, one dose of Japanese encephalitis attenuated live vaccine, and
two doses of group A meningococcal polysaccharide vaccine).
Results: A total of 6589 subjects (including 3785 community children and 2804 hospital newborns) were
included in this study; 97.34% of them received a timely ﬁrst dose of HB vaccine (24 h after birth) and
99.10% and 88.27% completed the HB vaccine series and the NIPV series, respectively. Among the
1680 children from eight counties who were rechecked, those with a timely ﬁrst dose of HB vaccine had
higher completion rates of the HB vaccine series and the NIPV series than those with a delayed ﬁrst dose
of HB vaccine (99.69% and 88.90% vs. 83.05% and 79.66%, respectively; both p < 0.001). Compared to
those with a delayed HB vaccine ﬁrst dose, the odds ratios for completing the HB vaccine series and the
NIPV series among children who received a timely ﬁrst dose of HB vaccine were 65.96 (95% conﬁdence
interval (CI) 21.73–200.25) and 3.24 (95% CI 1.81–5.81), respectively.
Conclusions: Coverage with a timely ﬁrst dose of HB vaccine is high in children in the community and
newborns in hospital, and timely receipt of the ﬁrst dose of HB vaccine is associated with an increased
likelihood of completing the HB vaccine series and the NIPV series in Fujian, China.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Infection with the hepatitis B virus (HBV) is highly prevalent in
Fujian, China. The prevalence of positivity for hepatitis B surface
antigen was estimated to be 10.2% in the population aged 1 to
59 years in 2006.1 To control HBV infection, hepatitis B vaccine* Corresponding author.
E-mail address: wjnhmm@126.com (J.-n. Wu).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(HB vaccine) has been recommended for newborns and infants
since 1992, and was included in the national immunization
program vaccine (NIPV) series in 2002.2 It is recommended that
infants receive three doses of HB vaccine, to be given within 24 h
after birth and at 1 month and 6 months of age.1,2
Many measures have been taken to improve coverage with a
timely ﬁrst dose of HB vaccine (within 24 h after birth) and
completion of the HB vaccine series since 2002, such as
the implementation of the free vaccine policy.1 Correspondingly,
the coverage rate for a timely HB vaccine ﬁrst dose increased fromciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
J.-n. Wu et al. / International Journal of Infectious Diseases 51 (2016) 62–65 6340–60% in 1992–2002 to around 90% in 2003–2005 in Fujian.1,3,4
However, previous studies have always evaluated coverage with a
timely HB vaccine ﬁrst dose in children in the community;1,3,4 the
level of vaccination among newborns in hospitals, and how
different the coverage is between children in the community and
newborns in hospital, remains unknown.
In addition, previous studies by the present investigators have
revealed that infants who receive a timely ﬁrst dose of HB vaccine
are more likely to complete the HB vaccine, diphtheria–tetanus–
pertussis (DTP), and measles-containing vaccine (MCV) series.1,5 In
the USA, administration of HB vaccine at birth was found to be
associated with the timely receipt of three doses of HB vaccine and
the 4:3:1 series (four doses of DTP vaccine, three doses of
poliomyelitis vaccine, and one dose of MCV),6 but not the 4:3:1:3
series (the 4:3:1 series plus three doses of Haemophilus inﬂuenzae
type b vaccine).7 However, the impact of timely initiation of the HB
vaccine ﬁrst dose on completion of the NIPV series in Fujian, China
is still unclear.
Therefore, a provincial NIPV series survey, including communi-
ty children and hospital infants, was conducted in 2013 to study
coverage with a timely ﬁrst dose of HB vaccine and to verify the
association between timely administration of the ﬁrst dose of HB
vaccine and completion of the HB vaccine series and the NIPV
series in Fujian, China, a region where HBV infection is highly
endemic,1 the immunization rate is high,3 and the vaccine series
and recommended vaccination schedules differ from those in the
USA.8,9
2. Methods
2.1. Survey design and data collection
The survey was conducted in May 2013 to obtain coverage rates
for the timely initiation of the HB vaccine ﬁrst dose and completion
of the HB vaccine and NIPV series among children in the
community born between January 1, 2010 and December 31,
2011. The target population was selected by stratiﬁed random
sampling. First, 18 random counties were selected from the nine
cities of Fujian (two counties in each city), and 30 villages were
identiﬁed in each selected county. Second, seven children who had
resided in the village for at least 3 months at the time of the survey
visit were selected by probability proportional to size sampling
(PPS). Finally, a house-to-house investigation was completed by
trained staff. Basic information, including date of birth, domicile,
and immunization history, was extracted from the child’s
immunization certiﬁcate kept by the parents.
Coverage of timely HB vaccine ﬁrst dose initiation was also
evaluated in hospital newborns. In each of the 18 counties, one
county-level hospital and two township hospitals were selected
randomly. At least 100 infants born between February 1 and
February 28, 2012 in each county hospital, as well as all infants
born between January 1 and December 31, 2012 in each of the
36 township hospitals, were investigated to calculate the coverage
rate of a timely administration of the ﬁrst dose of HB vaccine in
newborns. Information on the HB vaccine ﬁrst dose was obtained
from the immunization certiﬁcate kept by the parents, or the
immunization registry records kept by the hospitals. The nine
cities (and 18 counties) surveyed were Fuzhou (Minqing, Taijiang),
Xiamen (Huli, Haicang), Putian (Chengxiang, Xianyou), Sanming
(Shaxian, Mingxi), Quanzhou (Yongchun, Shishi), Zhangzhou
(Xiangcheng, Nanjing), Longyan (Xinluo, Yongding), Nanping
(Jianyang, Songxi), and Ningde (Fu’an, Zherong).
To further study the relationship between timely initiation of the
HB vaccine ﬁrst dose and completion of the HB vaccine and the NIPV
series, the immunization information of 1680 community children
from eight counties (Minqing, Huli, Xianyou, Shaxian, Yongchun,Xiangcheng, Xinluo, and Jianyang) were rechecked with the
vaccination records in the immunization surveillance system in
immunization clinics, and were summarized by initiation time of
the HB vaccine ﬁrst dose ( 24 vs. >24 h after birth) and completion
of the three-dose HB vaccine and the NIPV series (yes vs. no).
2.2. Outcome deﬁnitions
Three outcomes were assessed in this analysis: timely initiation
of the ﬁrst dose of HB vaccine, completion of the HB vaccine series,
and completion of the NIPV series. In accordance with the
recommended vaccination schedule of the China Center for
Disease Control and Prevention,3 timely initiation of the ﬁrst dose
of HB vaccine was deﬁned as receipt of the ﬁrst dose of HB vaccine
within 24 h after birth. Completion of the HB vaccine series was
deﬁned as the receipt of three doses of HB vaccine at the correct/
appropriate intervals (i.e., >1 month between doses 1 and 2, >2
months between doses 2 and 3, and >4 months between doses
1 and 3) by 12 months of age, regardless of the time at receipt of the
ﬁrst HB vaccine dose.
The NIPV series refers to three doses of HB vaccine, one dose of
Bacillus Calmette–Gue´rin vaccine (BCG), three doses of oral
poliomyelitis vaccine (OPV), three doses of DTP vaccine, one dose
of MCV, one dose of Japanese encephalitis attenuated live vaccine
(JEV-L), and two doses of group A meningococcal polysaccharide
vaccine (MPSV). Completion of the NIPV series was deﬁned as the
receipt of the NIPV series at the correct/appropriate intervals for
the different vaccines and/or doses, in which the child should have
completed the HB vaccine, BCG, OPV, DTP, MCV, and JEV-L series
and the ﬁrst dose of MPSV by 12 months of age, and have
completed the second dose of MPSV by 18 months of age (with an
interval of at least 3 months between the ﬁrst and second dose).
Community children aged less than 18 months at the time of the
survey were deemed to have completed the NIPV series if they had
received all NIPV series vaccines except the second dose of MPSV.
Any violation of the requirement was deﬁned as delayed initiation
of the HB vaccine ﬁrst dose, incompletion of the HB vaccine series,
and incompletion of the NIPV series, respectively.
2.3. Statistical analysis
Individual vaccination data were checked and classiﬁed
according to the deﬁnitions. The coverage rate of timely
administration of the HB vaccine ﬁrst dose was counted by city.
The Chi-square test or Fisher’s exact test was used to compare the
rates of timely HB vaccine ﬁrst dose between local children and
ﬂoating children, and between community children and hospital
infants. Local children were deﬁned as children with a permanent
local Hukou, while ﬂoating children were deﬁned as those living
without residence registration in the survey location.
The percentages of children who had completed the HB vaccine
series and the NIPV series were calculated by initiation time of the
HB vaccine ﬁrst dose (24 h and >24 h after birth). Odds ratios (OR)
and 95% conﬁdence intervals (95% CI) were calculated. A subgroup
analysis was done by urbanicity (rural area vs. urban area).
According to the distance between the area of residence and the
central city, and the economic development of the region, three
counties were classiﬁed as urban areas (Huli, Xiangcheng, and
Xinluo) and ﬁve counties were classiﬁed as rural areas (Minqing,
Xianyou, Shaxian, Yongchun, and Jianyang). Given the small sample
of the control group, details of the delay in HB vaccine ﬁrst dose
were described, and the proportion of children with a delayed HB
vaccine ﬁrst dose was compared between the two subgroups (rural
children vs. urban children; local children vs. ﬂoating children).
Pair-wise comparisons of heterogeneity were applied among
the ORs for relationships between the timely initiation of HB
J.-n. Wu et al. / International Journal of Infectious Diseases 51 (2016) 62–6564vaccine and completion of the HB vaccine series and completion of
the NIPV series.10 Heterogeneity in the ORs for the associations
between rural and urban areas was assessed separately.10
The level of statistical signiﬁcance was set at 0.05. All analyses
were completed using IBM SPSS Statistics version 19.0 (IBM Corp.,
Armonk, NY, USA).
3. Results
Immunization data for 6589 subjects, including 3785 commu-
nity children and 2804 hospital newborns, were included in this
study. Overall, 97.34% of subjects received the HB vaccine ﬁrst dose
within 24 h after birth. The completion rates of the HB vaccine
series and the NIPV series were 99.10% and 88.27%, respectively.
The coverage rates of timely HB vaccine ﬁrst dose among
community children and hospital newborns were 96.22% and
98.86%, respectively. The proportion of timely HB vaccine ﬁrst dose
among hospital newborns was signiﬁcantly higher than that
among community children (p < 0.001). Among community
children, local children had a slightly higher coverage rate of
timely HB vaccine ﬁrst dose than ﬂoating children; however, the
difference was not statistically signiﬁcant (96.41% vs. 94.44%;
p = 0.063) (Table 1).
Among the 1680 children from the eight counties, 96.49%
(1621/1680) had received a timely HB vaccine ﬁrst dose. The
percentages of children who had completed the HB vaccine series
and the NIPV series among the children with a timely HB vaccine
ﬁrst dose were 99.69% and 88.90%, respectively, while these were
83.05% and 71.19%, respectively, among children with a delayed
HB vaccine ﬁrst dose (both p < 0.001 for Chi-square test or Fisher’s
exact test) (Table 2).
Timely initiation of the HB vaccine ﬁrst dose was associated with
an increased likelihood of completion of the vaccine series.
Compared with children who received the ﬁrst dose of HB vaccine
at >24 h, the ORs for completing the HB vaccine series and the
NIPV series among children with a timely HB vaccine ﬁrst dose were
65.96 (95% CI 21.73–200.25) and 3.24 (95% CI 1.81–5.81),Table 1
Coverage rates of timely ﬁrst dose of hepatitis B vaccine in Fujian, by citya
City Community children born in 2010–2011 
Local children Floating children Tot
n % n % n 
Fuzhou 358 98.04 62 98.39 42
Xiamen 237 98.31 187 93.58b 42
Putian 418 99.28 2 100.00 42
Sanming 403 94.29 17 94.12 42
Quanzhou 381 98.43 39 94.87 42
Zhangzhou 407 94.59 13 92.31 42
Longyan 403 94.79 17 94.12 42
Nanping 404 95.05 16 93.75 42
Ningde 414 95.89 7 85.71 42
Total 3425 96.41 360 94.44 37
a Percentage of timely hepatitis B vaccine ﬁrst dose.
b p < 0.05 for the Chi-square test comparing the coverage rate of timely ﬁrst dose am
c p < 0.05 for the Chi-square test comparing the coverage rate of timely ﬁrst dose am
Table 2
Relationship between receipt of a timely ﬁrst dose of the HB vaccine and completion o
Time of initiation of HB vaccine ﬁrst dose No. surveyed Comp
% 
After 24 h 59 83.05
Within 24 h 1621 99.69
HB vaccine, hepatitis B vaccine; NIPV, national immunization program vaccine; OR, od
a p < 0.001 for the heterogeneity test comparing the OR with that for the associatiorespectively (Table 2). Signiﬁcant heterogeneity was found when
comparing the OR for the association between receipt of a timely HB
vaccine ﬁrst dose and completion of the NIPV series, with that for the
association between a timely initiation of the HB vaccine ﬁrst dose
and completion of the HB vaccine series (p < 0.001) (Table 2).
Children in the control group received the HB vaccine ﬁrst dose at
an average of 35 days of age (standard deviation 54.41 days), with a
range of 2–362 days. The proportion of children with a delayed HB
vaccine ﬁrst dose among local children was lower than that among
ﬂoating children (3.06% vs. 7.39%, p = 0.003). Similarly, the
percentage of children with a delayed HB vaccine ﬁrst dose in
urban areas was lower than that for rural areas (2.29% vs. 5.56%,
p < 0.001).
Sensitivity analyses indicated no signiﬁcant difference in the
associations between a timely initiation of HB vaccine ﬁrst dose
and completion of the HB vaccine series and the NIPV series among
children living in urban areas and those living in rural areas. The
corresponding ORs were 148.50 and 4.33 for urban children, and
29.17 and 3.27 for rural children, respectively (p-value for
urbanicity difference: 0.22 and 0.64, respectively).
4. Discussion
The coverage with a timely ﬁrst dose of HB vaccine in this study
was higher than that in previous studies,1,3,4 and higher than that
in other provinces and in the Global Alliance for Vaccine and
Immunization (GAVI) area of China.11–13 Unlike previous studies in
which the coverage with a timely HB vaccine ﬁrst dose has been
calculated based on community children alone, this study included
both community children and hospital newborns. Hence, the
sample in this study may be more representative than those
included in previous studies, because more and more newborns are
born in hospital rather than at home (about 99.7% of newborns
have been born in hospital since 201314). In addition, the difference
might be attributed to the implementation of policies and
approaches focusing on improving the coverage with a timely
HB vaccine ﬁrst dose since 2002, such as the provision of adequateHospital newborns
born in 2012
Total
al
% n % n %
0 98.10 300 100c 720 98.89
4 96.23 163 98.16 587 96.76
0 99.29 500 100.00 920 99.67
0 94.29 375 96.27 795 95.22
0 98.10 542 99.08 962 98.65
0 94.52 224 100c 644 96.43
0 94.76 200 100c 620 96.45
0 95.00 300 97.00 720 95.83
1 95.72 200 99.50c 621 96.94
85 96.22 2804 98.86c 6589 97.34
ong local children with that among ﬂoating children.
ong community children with that among hospital newborns.
f the HB vaccine series and the NIPV series
letion of HB vaccine series Completion of the NIPV series
OR (95% CI) % OR (95% CI)
 Reference 71.19 Reference
 65.96 (21.73–200.25) 88.90 3.24 (1.81–5.81)a
ds ratio; CI, conﬁdence interval.
n between a timely ﬁrst dose and completion of the HB vaccine series.
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child health and Expanded Program on Immunization (EPI)
departments, and the setting of assessment indicators for the
coverage with a timely HB vaccine ﬁrst dose for county-level
health bureaus.1,15,16
pt?>Similar to the results of the previous study by this study group,
timely HB vaccine ﬁrst dose administration was found to be associated
with an increased likelihood of completing the HB vaccine series.5
Generally, parents in high HBV endemic provinces maintain positive
attitudes towards HB vaccine immunization and are more concerned
about their children receiving prophylaxis against HBV infection.
Receiving a timely ﬁrst dose of HB vaccine might help emphasize the
importance of this vaccine to parents who may be motivated to have
their child complete subsequent doses.1,6,7,17,18
This appears to be the ﬁrst study to explore the association
between the receipt of a timely ﬁrst dose of HB vaccine and
completion of the NIPV series in Fujian, China. It was found that
children who received a timely HB vaccine ﬁrst dose were more
likely to complete the NIPV series, which is similar to ﬁndings in
the USA.6 The accomplishment of a timely HB vaccine ﬁrst dose
might prompt an educational intervention for the parents and
improve their compliance with vaccination. Further, it was found
that local and urban children were more likely to receive a timely
HB vaccine ﬁrst dose, which may reﬂect they have greater access to
medical care and/or come from families with a higher income;19,20
these advantages factors may make it more convenient and
affordable to complete the NIPV series. Alternatively, the HB
vaccine ﬁrst dose is often delayed as a result of false contra-
indications (e.g., low birth weight, prematurity),15,16 or for those
born at home,13,15 and the delay might affect appropriate catch-up
regimens for these children,21 resulting in them being less likely to
complete the HB vaccine and NIPV series.
Signiﬁcant heterogeneity in the ORs between completion of the
HB vaccine series and the NIPV series might reﬂect different
schedule durations for these vaccine series. Besides, other factors,
such as self-paid vaccine immunization, might inﬂuence the
completion of the NIPV series,22–24 but not affect the completion of
the HB vaccine series.
This study has several limitations. First, this was a rapid
evaluation of inoculation rates in children; only vaccination data
were collected, without other information such as the child’s sex,
age, and place of birth. Therefore, it was not possible to control for
confounders when examining the independent association be-
tween timely initiation of the HB vaccine and completion of the HB
vaccine series and NIPV series. Second, due to the interests of the
investigators, immunization data of community children from only
eight counties were included in the examination of the association
between timely initiation of the HB vaccine ﬁrst dose and
completion of the HB vaccine series and NIPV series, which might
somewhat affect the interpretation of the results. Finally, children
with a delayed birth dose of HB vaccine were set as the control
group; however, the sample size of this group was small and the
information collected was not sufﬁcient to have a good description
of these 59 children, e.g., why the vaccination was delayed.
In this quality assessment study including community children
and hospital newborns, it was found that coverage with a timely
HB vaccine ﬁrst dose was high in Fujian in 2013. A positive impact
of the timely initiation of the HB vaccine ﬁrst dose on completion of
the HB vaccine series and the NIPV series was also found. Policy
and related approaches should be continued and strengthened to
ensure that newborns receive their ﬁrst dose of HB vaccine on time.
Staff at EPI clinics should pay more attention to those with a
delayed HB vaccine ﬁrst dose to promote their completion of the
HB vaccine and NIPV series. Further studies should be conducted to
identify the reasons for the delay in the HB vaccine ﬁrst dose and to
draw up more comprehensive guidelines for newborns.Acknowledgements
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